JP5025888B2 - 目的の物質の生成に有用な鳥類の細胞系 - Google Patents
目的の物質の生成に有用な鳥類の細胞系 Download PDFInfo
- Publication number
- JP5025888B2 JP5025888B2 JP2003574808A JP2003574808A JP5025888B2 JP 5025888 B2 JP5025888 B2 JP 5025888B2 JP 2003574808 A JP2003574808 A JP 2003574808A JP 2003574808 A JP2003574808 A JP 2003574808A JP 5025888 B2 JP5025888 B2 JP 5025888B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- virus
- medium
- cell
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000271566 Aves Species 0.000 title claims abstract description 37
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 239000013076 target substance Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 49
- 230000001464 adherent effect Effects 0.000 claims abstract description 47
- 239000002609 medium Substances 0.000 claims abstract description 43
- 210000002966 serum Anatomy 0.000 claims abstract description 41
- 239000003102 growth factor Substances 0.000 claims abstract description 35
- 239000007640 basal medium Substances 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 255
- 241000700605 Viruses Species 0.000 claims description 82
- 210000000130 stem cell Anatomy 0.000 claims description 51
- 230000000694 effects Effects 0.000 claims description 25
- 239000001963 growth medium Substances 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 108010017842 Telomerase Proteins 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 18
- 102000004127 Cytokines Human genes 0.000 claims description 17
- 108090000695 Cytokines Proteins 0.000 claims description 17
- 241001430294 unidentified retrovirus Species 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000012679 serum free medium Substances 0.000 claims description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 7
- 101710177504 Kit ligand Proteins 0.000 claims description 7
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- 241000710799 Rubella virus Species 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 5
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 201000005505 Measles Diseases 0.000 claims description 5
- 241000712079 Measles morbillivirus Species 0.000 claims description 5
- 208000005647 Mumps Diseases 0.000 claims description 5
- 241000711386 Mumps virus Species 0.000 claims description 5
- 239000012737 fresh medium Substances 0.000 claims description 5
- 208000010805 mumps infectious disease Diseases 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 4
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 4
- 102000003815 Interleukin-11 Human genes 0.000 claims description 4
- 108090000177 Interleukin-11 Proteins 0.000 claims description 4
- HPFXACZRFJDURI-KTKRTIGZSA-N N-oleoylglycine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCC(O)=O HPFXACZRFJDURI-KTKRTIGZSA-N 0.000 claims description 4
- 241000709664 Picornaviridae Species 0.000 claims description 4
- 102100038126 Tenascin Human genes 0.000 claims description 4
- 108010008125 Tenascin Proteins 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 235000020776 essential amino acid Nutrition 0.000 claims description 4
- 239000003797 essential amino acid Substances 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 102100020880 Kit ligand Human genes 0.000 claims description 3
- 230000000721 bacterilogical effect Effects 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 239000012894 fetal calf serum Substances 0.000 claims description 3
- 229940054269 sodium pyruvate Drugs 0.000 claims description 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 210000001172 blastoderm Anatomy 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000012091 fetal bovine serum Substances 0.000 claims description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 2
- 238000011031 large-scale manufacturing process Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 241000702263 Reovirus sp. Species 0.000 claims 2
- 230000012010 growth Effects 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 4
- 230000000750 progressive effect Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 210000002950 fibroblast Anatomy 0.000 description 13
- 239000004033 plastic Substances 0.000 description 11
- 229920003023 plastic Polymers 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 10
- 230000010076 replication Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000001988 somatic stem cell Anatomy 0.000 description 5
- 108091035539 telomere Proteins 0.000 description 5
- 210000003411 telomere Anatomy 0.000 description 5
- 102000055501 telomere Human genes 0.000 description 5
- 241000714230 Avian leukemia virus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000036978 cell physiology Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000017830 lymphoblastoma Diseases 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 241000725585 Chicken anemia virus Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000702244 Orthoreovirus Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- -1 b-FGF Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000000275 quality assurance Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 229940123373 Adenovirus E1A gene Drugs 0.000 description 1
- 241001519465 Avian metapneumovirus Species 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 1
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- 241001531946 Gallid herpesvirus Species 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 1
- 108700038332 Histone deacetylase 11 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000620147 Human mastadenovirus C Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102220575132 Leucine-rich repeat transmembrane protein FLRT1_S86N_mutation Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101000716728 Mus musculus Kit ligand Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 241001081488 Turkey aviadenovirus B Species 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 241000701792 avian adenovirus Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000722 genetic damage Toxicity 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 101150024228 mdm2 gene Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/92—Medium free of human- or animal-derived components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Farming Of Fish And Shellfish (AREA)
- Peptides Or Proteins (AREA)
- Feeding And Watering For Cattle Raising And Animal Husbandry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0202945A FR2836924B1 (fr) | 2002-03-08 | 2002-03-08 | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| FR02/02945 | 2002-03-08 | ||
| PCT/FR2003/000735 WO2003076601A1 (fr) | 2002-03-08 | 2003-03-07 | Lignées de cellules aviaires utiles pour la production de substances d'intérêt |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012026135A Division JP5784521B2 (ja) | 2002-03-08 | 2012-02-09 | 目的の物質の生成に有用な鳥類の細胞系 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005525803A JP2005525803A (ja) | 2005-09-02 |
| JP2005525803A5 JP2005525803A5 (https=) | 2009-10-22 |
| JP5025888B2 true JP5025888B2 (ja) | 2012-09-12 |
Family
ID=27763651
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574808A Expired - Fee Related JP5025888B2 (ja) | 2002-03-08 | 2003-03-07 | 目的の物質の生成に有用な鳥類の細胞系 |
| JP2012026135A Expired - Lifetime JP5784521B2 (ja) | 2002-03-08 | 2012-02-09 | 目的の物質の生成に有用な鳥類の細胞系 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012026135A Expired - Lifetime JP5784521B2 (ja) | 2002-03-08 | 2012-02-09 | 目的の物質の生成に有用な鳥類の細胞系 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20040058441A1 (https=) |
| EP (2) | EP1483369B1 (https=) |
| JP (2) | JP5025888B2 (https=) |
| CN (2) | CN101676388B (https=) |
| AT (1) | ATE408004T1 (https=) |
| AU (1) | AU2003227820B2 (https=) |
| CA (1) | CA2478125C (https=) |
| DE (1) | DE60323468D1 (https=) |
| DK (1) | DK1483369T3 (https=) |
| ES (1) | ES2312775T3 (https=) |
| FR (1) | FR2836924B1 (https=) |
| PT (1) | PT1483369E (https=) |
| SI (1) | SI1483369T1 (https=) |
| WO (1) | WO2003076601A1 (https=) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7445924B2 (en) * | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| US20060191026A1 (en) | 2005-02-18 | 2006-08-24 | Origen Therapeutics, Inc. | Tissue specific expression of antibodies in chickens |
| US7145057B2 (en) | 2002-02-01 | 2006-12-05 | Origen Therapeutics, Inc. | Chimeric bird from embryonic stem cells |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| JP2005537793A (ja) | 2002-09-05 | 2005-12-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法 |
| CN1726276A (zh) * | 2002-12-13 | 2006-01-25 | 艾文蒂斯·帕斯图尔公司 | Alvac在禽胚胎干细胞上的生产 |
| EP1500699A1 (en) * | 2003-07-22 | 2005-01-26 | Vivalis | Production of vaccinia virus with adherent or non adherent avian cell lines |
| EP1646715B1 (en) | 2003-07-22 | 2010-05-12 | Vivalis | Production of poxviruses with adherent or non adherent avian cell lines |
| WO2005028634A2 (en) * | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| US20090104226A1 (en) | 2004-05-21 | 2009-04-23 | Novartis Vaccines And Diagnostics Inc. | Alphavirus Vectors for Respiratory Pathogen Vaccines |
| JP2008512443A (ja) | 2004-09-09 | 2008-04-24 | カイロン ベーリング ゲーエムベーハー アンド カンパニー | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
| EP2923711A1 (en) * | 2004-11-03 | 2015-09-30 | Novartis Vaccines and Diagnostics, Inc. | Influenza vaccination |
| FR2878860A1 (fr) * | 2004-12-08 | 2006-06-09 | Vivalis Sa | Lignees de cellules souches humaines derivees de cellules es et utilisations pour la production de vaccins et de proteines recombinantes |
| FR2884255B1 (fr) * | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| AU2011253998B2 (en) * | 2005-04-11 | 2014-04-24 | Valneva | Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines |
| CA2627971A1 (en) | 2005-11-01 | 2007-05-10 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
| ES2420829T3 (es) | 2005-11-04 | 2013-08-27 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular |
| EP1951298A1 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
| EP3753574A1 (en) | 2006-01-27 | 2020-12-23 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
| FR2898909A1 (fr) | 2006-03-24 | 2007-09-28 | Agronomique Inst Nat Rech | Combinaison de marqueurs de cellules aviaires |
| EP2004226A1 (en) | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Storage of influenza vaccines without refrigeration |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP2500417A1 (en) | 2006-08-09 | 2012-09-19 | Vivalis | Method of production of transgenic avian using embryonic stem cells |
| ES2536401T3 (es) | 2006-09-11 | 2015-05-25 | Novartis Ag | Fabricación de vacunas contra virus de la gripe sin usar huevos |
| SG177141A1 (en) | 2006-12-06 | 2012-01-30 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
| CN100443588C (zh) * | 2006-12-11 | 2008-12-17 | 中国农业科学院北京畜牧兽医研究所 | 静宁鸡胚成纤维细胞系及其培养方法 |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| EP1995309A1 (en) * | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
| CA2691868C (en) * | 2007-07-03 | 2016-12-20 | Transgene S.A. | Immortalized avian cell lines |
| US20090028831A1 (en) * | 2007-07-23 | 2009-01-29 | University Of Kentucky Research Foundation | Stem cell regulator, compositions and methods of use |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| AU2008339631B2 (en) | 2007-12-24 | 2014-07-24 | Novartis Ag | Assays for adsorbed influenza vaccines |
| US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| AU2009244776B2 (en) * | 2008-02-25 | 2013-03-07 | Nanotherapeutics, Inc. | Method for producing continuous cell lines |
| WO2009115917A2 (en) | 2008-03-18 | 2009-09-24 | Novartis Ag | Improvements in preparation of influenza virus vaccine antigens |
| WO2009132195A1 (en) * | 2008-04-23 | 2009-10-29 | Michigan State University | Immortal avian cell line and methods of use |
| ES2539045T3 (es) | 2009-01-19 | 2015-06-25 | Innate Pharma | Anticuerpos anti-KIR3D |
| WO2010092479A2 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with reduced amounts of squalene |
| SI2396030T1 (sl) | 2009-02-10 | 2015-12-31 | Novartis Ag | Sheme dajanja cepiva proti gripi za seve, povezane s pandemijo |
| AU2010212548A1 (en) | 2009-02-10 | 2011-09-15 | Novartis Ag | Influenza vaccines with increased amounts of H3 antigen |
| FR2949344A1 (fr) | 2009-04-27 | 2011-03-04 | Novartis Ag | Vaccins de protection contre la grippe |
| EP4218799A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| GB0918830D0 (en) | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
| GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
| CA3177833A1 (en) | 2009-12-15 | 2011-06-15 | University Of Saskatchewan | Vaccines for inclusion body hepatitis |
| WO2011095596A1 (en) | 2010-02-04 | 2011-08-11 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
| FR2956409A1 (fr) | 2010-02-15 | 2011-08-19 | Univ Claude Bernard Lyon | Procedes pour optimiser la production virale par l'inactivation ou l'inhibition du gene hipk2 et cellules modifiees pour la production virale |
| ES2528010T5 (es) | 2010-03-08 | 2018-02-19 | Novartis Ag | Métodos para detectar la presencia de patógenos intracelulares |
| WO2011124635A1 (en) | 2010-04-07 | 2011-10-13 | Humalys | Binding molecules against chikungunya virus and uses thereof |
| EP2374816B1 (en) | 2010-04-07 | 2016-09-28 | Agency For Science, Technology And Research | Binding molecules against Chikungunya virus and uses thereof |
| BR112012025364A2 (pt) | 2010-04-07 | 2015-09-22 | Novartis Ag | método para geração de partícula semelhante a vírus de parvovírus b19 |
| WO2011138682A2 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
| AU2011254204B2 (en) | 2010-05-21 | 2015-08-20 | Seqirus UK Limited | Influenza virus reassortment method |
| EP2575872B1 (en) | 2010-06-01 | 2020-08-19 | Seqirus UK Limited | Concentration of influenza vaccine antigens without lyophilization |
| CA2801151A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| AU2011276328C1 (en) | 2010-07-06 | 2016-01-21 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
| ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
| CA2810488C (en) | 2010-09-07 | 2025-05-06 | Technion Research & Development Foundation Limited | NEW PROCESSES AND CULTURE MEDIA FOR THE CULTURE OF MULTIPOTENTED STEM CELLS |
| FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
| WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
| AU2012211278B2 (en) | 2011-01-26 | 2016-11-10 | Glaxosmithkline Biologicals Sa | RSV immunization regimen |
| DK2707385T3 (da) | 2011-05-13 | 2017-11-20 | Glaxosmithkline Biologicals Sa | RSV-F-præfusionsantigener |
| US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
| WO2013045658A1 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
| WO2013054199A2 (en) | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
| GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| EP2660316A1 (en) | 2012-05-02 | 2013-11-06 | Helmholtz-Zentrum für Infektionsforschung GmbH | Avian cell line and its use in production of protein |
| US20150140068A1 (en) | 2012-07-06 | 2015-05-21 | Novartis Ag | Immunogenic compositions and uses thereof |
| CN104640564B (zh) | 2012-07-10 | 2020-08-04 | 特兰斯吉恩股份有限公司 | 分枝杆菌抗原疫苗 |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| EA201590683A1 (ru) | 2012-11-20 | 2015-11-30 | Глаксосмитклайн Байолоджикалс С.А. | Тримеры rsv f, предшествующие слиянию |
| US20140255447A1 (en) * | 2013-03-05 | 2014-09-11 | Biomune Company | Production of avian embryo cells |
| FR3008992A1 (fr) * | 2013-07-25 | 2015-01-30 | Agronomique Inst Nat Rech | Procede de selection d'une lignee cellulaire permissive pour la replication de virus aviaires |
| EP3092000A1 (en) | 2014-01-09 | 2016-11-16 | Transgene SA | Fusion of heterooligomeric mycobacterial antigens |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| EP3031822A1 (en) | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| ES2876412T3 (es) | 2014-12-17 | 2021-11-12 | Fundacion Para La Investig Medica Aplicada | Construcciones de ácido nucleico y vectores de terapia génica para su uso en el tratamiento de la enfermedad de Wilson |
| EP3233129B1 (en) | 2014-12-17 | 2020-01-15 | Fundacion para la Investigacion Medica Aplicada | Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions |
| EP3047856A1 (en) | 2015-01-23 | 2016-07-27 | Novartis AG | Cmv antigens and uses thereof |
| HK1254344A1 (zh) | 2015-06-26 | 2019-07-19 | Seqirus UK Limited | 抗原匹配的流感疫苗 |
| HUE051783T2 (hu) | 2015-07-07 | 2021-03-29 | Seqirus Uk Ltd | Eljárás immunogén hemagglutinin mennyiségi meghatározására |
| MX2019011599A (es) | 2017-03-30 | 2019-12-19 | Univ Queensland | Moleculas quimericas y usos de las mismas. |
| WO2019040994A1 (en) | 2017-09-01 | 2019-03-07 | The Australian National University | IMMUNOREGULATOR MOLECULES AND USES THEREOF |
| IL274926B2 (en) | 2017-12-01 | 2026-04-01 | Encoded Therapeutics Inc | Pyrazolopyrimidines with activity against respiratory syncytial virus |
| WO2019219649A1 (en) | 2018-05-14 | 2019-11-21 | Vivet Therapeutics | Gene therapy vectors comprising s/mar sequences |
| KR20210016446A (ko) | 2018-05-30 | 2021-02-15 | 인스티튜트 포 리서치 인 바이오메드슨 | 내인성 활성화-유도 시티딘 탈아미노효소를 이용한 b 림프구의 조작 |
| WO2020012037A1 (en) | 2018-07-13 | 2020-01-16 | Valneva Se | Method for rescuing and producing a virus in avian cells |
| SG11202103681UA (en) | 2018-10-12 | 2021-05-28 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
| SG11202104634UA (en) | 2018-11-07 | 2021-06-29 | Vivet Therapeutics | Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2) |
| TW202039854A (zh) | 2018-11-16 | 2020-11-01 | 美商編碼製藥公司 | 治療威爾遜氏病的組合物和方法 |
| WO2020104650A1 (en) | 2018-11-23 | 2020-05-28 | Valneva Se | Food products comprising avian stem cells |
| JP7664856B2 (ja) | 2019-05-22 | 2025-04-18 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | ヒト多能性細胞を培養する方法 |
| WO2020243651A1 (en) | 2019-05-29 | 2020-12-03 | Encoded Therapeutics, Inc. | Compositions and methods for selective gene regulation |
| CN114222818B (zh) | 2019-07-02 | 2025-07-08 | 基础应用医学研究基金会 | cPLA2e诱导剂及其用途 |
| KR20220035457A (ko) | 2019-07-21 | 2022-03-22 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 치료 바이러스 백신 |
| EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
| CN114554866B (zh) * | 2019-09-10 | 2024-08-16 | 必要肉制品公司 | 用于生产食物产品的禽类干细胞 |
| JP2023502650A (ja) | 2019-11-18 | 2023-01-25 | セキラス ピーティーワイ リミテッド | 遺伝子再集合インフルエンザウイルスを産生するための方法 |
| EP4192961A2 (en) | 2020-08-06 | 2023-06-14 | Fundacion para la Investigacion Medica Aplicada | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy |
| US20230265456A1 (en) | 2020-08-10 | 2023-08-24 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
| IL301255A (en) | 2020-10-09 | 2023-05-01 | UCB Biopharma SRL | Nucleic acid structures, viral vectors and viral particles |
| US20240091382A1 (en) | 2020-12-23 | 2024-03-21 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
| EP4032547A1 (en) | 2021-01-20 | 2022-07-27 | GlaxoSmithKline Biologicals S.A. | Hsv1 fce derived fragements for the treatment of hsv |
| US20240417434A1 (en) | 2021-10-28 | 2024-12-19 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
| US20250101067A1 (en) | 2022-01-28 | 2025-03-27 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
| CN114480286B (zh) * | 2022-02-16 | 2024-05-31 | 上海健士拜生物科技有限公司 | 无血清悬浮型lmh细胞系及其制备方法和应用 |
| CN116656628A (zh) * | 2023-07-31 | 2023-08-29 | 深圳市卫光生物制品股份有限公司 | 一种痘病毒载体疫苗的制备方法 |
| EP4567102A1 (en) | 2023-12-05 | 2025-06-11 | Suprême | Methods for isolating embryonic stem cells from avian embryonic cells |
| CN118956737A (zh) * | 2024-07-17 | 2024-11-15 | 广州沃亘生物科技有限公司 | 一种长期维持df-1细胞活力的培养基及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4388298A (en) | 1982-07-14 | 1983-06-14 | The United States Of America As Represented By The Secretary Of Agriculture | Propagation of hemorrhagic enteritis virus in a turkey cell line and vaccine produced |
| JP2740320B2 (ja) | 1988-08-04 | 1998-04-15 | アムラド・コーポレイション・リミテッド | 胚幹細胞のインビトロ増殖 |
| US5162215A (en) * | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
| US5388680A (en) | 1990-10-09 | 1995-02-14 | Intellicall, Inc. | Coin handling system with an improved coin chute |
| DK0594743T3 (da) | 1991-07-12 | 1999-12-20 | Pfizer | Kontinuert cellelinje og vaccine mod aviær coccidia |
| JPH05227947A (ja) | 1992-01-14 | 1993-09-07 | Rikagaku Kenkyusho | 鳥類原始生殖細胞の分離方法 |
| AU3597093A (en) | 1992-01-27 | 1993-09-01 | Embrex Inc. | Gene transfer in poultry by introduction of embryo cells (in ovo) |
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| WO1994003585A1 (en) | 1992-08-04 | 1994-02-17 | Commonwealth Scientific And Industrial Research Organisation | A method for maintaining embryonic stem cells and avian factor useful for same |
| US5453357A (en) * | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
| US5589458A (en) * | 1992-11-13 | 1996-12-31 | Thomas Jefferson University | Compounds that inhibit T cell proliferation and methods for using the same |
| FR2726003B1 (fr) * | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
| US5989805A (en) | 1995-10-27 | 1999-11-23 | Board Of Trustees Operating Michigan State University | Immortal avian cell line to grow avian and animal viruses to produce vaccines |
| FR2749022B1 (fr) | 1996-05-23 | 2001-06-01 | Rhone Merieux | Cellules aviaires immortelles |
| US5691200A (en) | 1996-07-03 | 1997-11-25 | The United States Of America As Represented By The Secretary Of Agriculture | Method to produce granulocyte colony stimulating factor from immortalized avian T lymphocytes and method to produce immortalized cells |
| US5830723A (en) | 1996-08-13 | 1998-11-03 | Regents Of The University Of Minnesota | Method for immortalizing chicken cells |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| JP4543402B2 (ja) | 1996-10-10 | 2010-09-15 | ライフ テクノロジーズ コーポレーション | 植物由来栄養素を含む動物細胞培養培地 |
| ATE271122T1 (de) | 1996-11-12 | 2004-07-15 | Pfizer | Attenuierter lebender neospora impfstoff |
| EP1019491B1 (en) * | 1997-08-04 | 2005-12-07 | University of Massachusetts, a Public Institution of Higher Education of The Commonwealth of Massachusetts, | Production of avian embryonic germ (eg) cell lines by prolonged culturing of pgcs, use thereof for cloning and chimerization |
| AU736087B2 (en) * | 1997-08-04 | 2001-07-26 | University Of Massachusetts | Avian primordial germ cell (PGC) cell line and a method for long term culturing thereof |
| US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
| ATE378398T1 (de) * | 1999-02-11 | 2007-11-15 | Hanmi Pharm Ind Co Ltd | Pluripotente embryonale keimzellinie aus vögeln |
| WO2001016294A2 (en) * | 1999-08-27 | 2001-03-08 | Invitrogen Corporation | Metal binding compounds and their use in cell culture medium compositions |
| DE19947407C2 (de) | 1999-10-01 | 2002-08-01 | Bayerische Motoren Werke Ag | Datenbussystem für Kraftfahrzeuge |
| WO2002086073A2 (en) * | 2001-04-20 | 2002-10-31 | Memorial Sloan-Kettering Cancer Center | Generation of differentiated tissue from nuclear transfer embryonic stem cells and methods of use |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| PT2287288E (pt) | 2002-07-09 | 2012-12-10 | Baxter Int | Meio isento de proteína animal para cultura de células |
| EP1500699A1 (en) | 2003-07-22 | 2005-01-26 | Vivalis | Production of vaccinia virus with adherent or non adherent avian cell lines |
| EP1646715B1 (en) | 2003-07-22 | 2010-05-12 | Vivalis | Production of poxviruses with adherent or non adherent avian cell lines |
| KR100552844B1 (ko) * | 2003-12-31 | 2006-02-21 | 동부아남반도체 주식회사 | 반도체 소자의 제조 방법 |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| WO2007135133A1 (en) | 2006-05-19 | 2007-11-29 | Vivalis | Avian cell lines derived from primordial germ cells useful for the production of substances of interest |
| EP2500417A1 (en) | 2006-08-09 | 2012-09-19 | Vivalis | Method of production of transgenic avian using embryonic stem cells |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
-
2002
- 2002-03-08 FR FR0202945A patent/FR2836924B1/fr not_active Expired - Lifetime
-
2003
- 2003-03-07 ES ES03725273T patent/ES2312775T3/es not_active Expired - Lifetime
- 2003-03-07 CN CN2009101796309A patent/CN101676388B/zh not_active Expired - Lifetime
- 2003-03-07 CN CNB038101203A patent/CN100562567C/zh not_active Expired - Fee Related
- 2003-03-07 JP JP2003574808A patent/JP5025888B2/ja not_active Expired - Fee Related
- 2003-03-07 EP EP03725273A patent/EP1483369B1/fr not_active Expired - Lifetime
- 2003-03-07 AT AT03725273T patent/ATE408004T1/de active
- 2003-03-07 EP EP08163979.1A patent/EP1992687B1/fr not_active Expired - Lifetime
- 2003-03-07 DK DK03725273T patent/DK1483369T3/da active
- 2003-03-07 AU AU2003227820A patent/AU2003227820B2/en not_active Expired
- 2003-03-07 DE DE60323468T patent/DE60323468D1/de not_active Expired - Lifetime
- 2003-03-07 PT PT03725273T patent/PT1483369E/pt unknown
- 2003-03-07 WO PCT/FR2003/000735 patent/WO2003076601A1/fr not_active Ceased
- 2003-03-07 CA CA2478125A patent/CA2478125C/fr not_active Expired - Fee Related
- 2003-03-07 SI SI200331354T patent/SI1483369T1/sl unknown
- 2003-07-24 US US10/625,847 patent/US20040058441A1/en not_active Abandoned
-
2009
- 2009-01-08 US US12/350,781 patent/US20090239297A1/en not_active Abandoned
-
2010
- 2010-03-03 US US12/717,096 patent/US9382513B2/en not_active Expired - Fee Related
-
2011
- 2011-08-09 US US13/206,056 patent/US20110294209A1/en not_active Abandoned
-
2012
- 2012-02-09 JP JP2012026135A patent/JP5784521B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2478125A1 (fr) | 2003-09-18 |
| HK1142094A1 (en) | 2010-11-26 |
| AU2003227820B2 (en) | 2008-04-03 |
| CN1649999A (zh) | 2005-08-03 |
| JP2012110344A (ja) | 2012-06-14 |
| EP1992687A3 (fr) | 2009-03-25 |
| US9382513B2 (en) | 2016-07-05 |
| JP5784521B2 (ja) | 2015-09-24 |
| FR2836924A1 (fr) | 2003-09-12 |
| CN100562567C (zh) | 2009-11-25 |
| CA2478125C (fr) | 2013-05-07 |
| SI1483369T1 (sl) | 2008-12-31 |
| EP1483369B1 (fr) | 2008-09-10 |
| AU2003227820A1 (en) | 2003-09-22 |
| US20110294209A1 (en) | 2011-12-01 |
| EP1483369A1 (fr) | 2004-12-08 |
| DK1483369T3 (da) | 2008-12-01 |
| PT1483369E (pt) | 2008-12-17 |
| CN101676388B (zh) | 2013-09-04 |
| ES2312775T3 (es) | 2009-03-01 |
| ATE408004T1 (de) | 2008-09-15 |
| CN101676388A (zh) | 2010-03-24 |
| WO2003076601A8 (fr) | 2005-05-12 |
| US20100221825A1 (en) | 2010-09-02 |
| DE60323468D1 (de) | 2008-10-23 |
| US20120070893A9 (en) | 2012-03-22 |
| EP1992687B1 (fr) | 2019-06-26 |
| WO2003076601A1 (fr) | 2003-09-18 |
| EP1992687A2 (fr) | 2008-11-19 |
| JP2005525803A (ja) | 2005-09-02 |
| FR2836924B1 (fr) | 2005-01-14 |
| US20040058441A1 (en) | 2004-03-25 |
| US20090239297A1 (en) | 2009-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5025888B2 (ja) | 目的の物質の生成に有用な鳥類の細胞系 | |
| JP4787156B2 (ja) | 付着または非付着の鳥類細胞系を用いた、ポックスウィルスの作製法 | |
| US20020072117A1 (en) | Human feeder cells that support proliferation of undifferentiated pluripotent stem cells | |
| EA021064B1 (ru) | Непрерывные генетически стабильные птичьи клеточные линии, полученные из эмбрионов, способ их получения и их применение для производства вирусных вакцин, рекомбинантных белков и пептидов | |
| JP4149518B2 (ja) | トリ不死細胞 | |
| JP5067765B2 (ja) | 卵膜由来細胞の細胞外マトリクスを用いた多能性幹細胞の培養方法 | |
| US7413904B2 (en) | Human embryonic stem cells having genetic modifications | |
| JP7729630B2 (ja) | ｉＰＳＣ誘導 | |
| EP1500699A1 (en) | Production of vaccinia virus with adherent or non adherent avian cell lines | |
| HK1142094B (en) | Avian cell lines for the production of useful substances | |
| US20080085554A1 (en) | Culture Medium for Culturing Feeder Cells for Embryonic Stem Cells Culture and the Prepared Feeder Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060203 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090304 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090529 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090605 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090702 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090709 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090731 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090807 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090904 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090904 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100913 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101130 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101207 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111012 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120209 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120302 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120502 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120525 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120618 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120620 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150629 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |